Renal Cancer - Results from #1620

Albumin-to-Alkaline Phosphatase Ratio as a Novel Prognostic Factor in Patients Undergoing Nephrectomy for Non-Metastatic Renal Cell Carcinoma: Propensity Score Matching Analysis. March 11, 2022

Immune Checkpoint Inhibitor Combination Therapy for Renal Cell Carcinomas With Concomitant Inferior Vena Cava Thrombi. March 10, 2022

Coordinated Pembrolizumab and High Dose IL-2 (5-in-a-Row Schedule) for Therapy of Metastatic Clear Cell Renal Cancer. March 10, 2022

Risk factors of proteinuria and potentially protective effect of renin-angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib. March 9, 2022

Construction of a Lactate-Related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Kidney Renal Clear Cell Carcinoma. March 9, 2022

The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. March 8, 2022

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib. March 8, 2022

Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma. March 7, 2022

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial. March 7, 2022

Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries. March 7, 2022

Superior Mesenteric Artery Injury During Robot-assisted Laparoscopic Nephrectomy: A Robotic Nightmare. March 7, 2022

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial. March 4, 2022

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. March 4, 2022

Anti-Cancer Activity of PAK4/NAMPT Inhibitor and Programmed Cell Death Protein-1 Antibody in Kidney Cancer. March 3, 2022

The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: A Real World Multi-Institutional Analysis. March 3, 2022

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study. March 2, 2022

Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer. March 2, 2022

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial. March 1, 2022

Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives. March 1, 2022

Novel Imaging Methods for Renal Mass Characterization: A Collaborative Review. February 28, 2022

Page 82 of 457